In this episode of Medsider Radio, we sat down with David Veino, President and CEO of Neuros Medical.

Neuros is commercializing the FDA-approved Altius Direct Electrical Nerve Stimulation System for chronic post-amputation pain.

Before Neuros, David held senior commercial leadership roles at Cardiovascular Systems (CSI) and Stryker, and helped grow CSI's coronary and peripheral business from approximately $50 million to more than $250 million in annual revenue while leading key amputation-prevention initiatives. He also serves as a private equity advisor with Sectoral Asset Management. 

In this interview, David discusses how commercialization begins by mapping the patient journey upstream, what it takes to generate gold-standard clinical evidence for a novel therapy, how investors assess scalable medtech businesses, and how to build an investor pitch that earns the next meeting.  

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

And if you’re ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.

These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.

If you'd rather read than listen, here's a link to the full interview with David Veino, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!

KEY MOMENTS FROM THE INTERVIEW

• (03:02) - David's 30-year medtech journey from cardiovascular devices to leading Neuros
• (04:38) - How Neuros is treating chronic post-amputation pain with on-demand neuromodulation
• (11:08) - Why Neuros completely changed its strategy halfway through the pivotal trial
• (15:36) - Why commercialization starts with referral pathways, not end-users
• (18:09) - How prosthetists became one of Neuros' most important referral sources
• (26:11) - What it takes to generate gold-standard clinical evidence for a first-of-its-kind therapy
• (37:41) - Building an investor pitch that earns the next meeting
• (41:42) - What gets David excited enough to invest in a medtech company